| Year |
Citation |
Score |
| 2023 |
Shoari A, Khalili-Tanha G, Coban MA, Radisky ES. Structure and computation-guided yeast surface display for the evolution of TIMP-based matrix metalloproteinase inhibitors. Frontiers in Molecular Biosciences. 10: 1321956. PMID 38074088 DOI: 10.3389/fmolb.2023.1321956 |
0.344 |
|
| 2023 |
Bonadio A, Wenig BL, Hockla A, Radisky ES, Shifman JM. Designed Loop Extension Followed by Combinatorial Screening Confers High Specificity to a Broad Matrix MetalloproteinaseInhibitor. Journal of Molecular Biology. 435: 168095. PMID 37068580 DOI: 10.1016/j.jmb.2023.168095 |
0.376 |
|
| 2023 |
Hayun H, Coban M, Bhagat AK, Ozer E, Alfonta L, Caulfield TR, Radisky ES, Papo N. Utilizing genetic code expansion to modify N-TIMP2 specificity towards MMP-2, MMP-9, and MMP-14. Scientific Reports. 13: 5186. PMID 36997589 DOI: 10.1038/s41598-023-32019-3 |
0.343 |
|
| 2023 |
Hayun H, Coban M, Bhagat AK, Ozer E, Alfonta L, Caulfield TR, Radisky ES, Papo N. Utilizing genetic code expansion to modify N-TIMP2 specificity towards MMP-2, MMP-9, and MMP-14. Research Square. PMID 36712032 DOI: 10.21203/rs.3.rs-2446107/v1 |
0.343 |
|
| 2022 |
Mehner C, Hockla A, Coban M, Madden B, Estrada R, Radisky DC, Radisky ES. Activity-based protein profiling reveals active serine proteases that drive malignancy of human ovarian clear cell carcinoma. The Journal of Biological Chemistry. 102146. PMID 35716777 DOI: 10.1016/j.jbc.2022.102146 |
0.306 |
|
| 2022 |
Coban M, Maina E, Raeeszadeh-Sarmazdeh M, Caulfield TR, Radisky ES. Structural and computational investigation of MMP-3 affinity improvements with an engineered TIMP-1 inhibitor. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 35556538 DOI: 10.1096/fasebj.2022.36.S1.R3528 |
0.363 |
|
| 2022 |
Raeeszadeh-Sarmazdeh M, Coban M, Mahajan S, Hockla A, Sankaran B, Downey GP, Radisky DC, Radisky ES. Engineering of tissue inhibitor of metalloproteinases TIMP-1 for fine discrimination between closely-related stromelysins MMP-3 and MMP-10. The Journal of Biological Chemistry. 101654. PMID 35101440 DOI: 10.1016/j.jbc.2022.101654 |
0.701 |
|
| 2021 |
Gabasa M, Radisky ES, Ikemori R, Bertolini G, Arshakyan M, Hockla A, Duch P, Rondinone O, Llorente A, Maqueda M, Davalos A, Gavilán E, Perera A, Ramírez J, Gascón P, et al. MMP1 drives tumor progression in large cell carcinoma of the lung through fibroblast senescence. Cancer Letters. PMID 33684534 DOI: 10.1016/j.canlet.2021.01.028 |
0.315 |
|
| 2020 |
Mehner C, Miller E, Hockla A, Coban M, Weroha SJ, Radisky DC, Radisky ES. Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma. Oncogene. PMID 32929152 DOI: 10.1038/S41388-020-01451-4 |
0.348 |
|
| 2020 |
Aharon L, Aharoni SL, Radisky ES, Papo N. Quantitative Mapping of Binding Specificity Landscapes for Homologous Targets by using a High‑Throughput Method. The Biochemical Journal. PMID 32296833 DOI: 10.1042/Bcj20200188 |
0.449 |
|
| 2020 |
Kojima Y, Machida Y, Palani S, Caulfield TR, Radisky ES, Kaufmann SH, Machida YJ. FAM111A protects replication forks from protein obstacles via its trypsin-like domain. Nature Communications. 11: 1318. PMID 32165630 DOI: 10.1038/S41467-020-15170-7 |
0.31 |
|
| 2020 |
Gabasa M, Ikemori R, Arshakyan M, Radisky E, Reguard N, Radisky D, Alcaraz J. Abstract 5099: Large-cell neuroendocrine carcinoma cells of the lung induce a tumor-promoting senescent phenotype in fibroblasts through MMP1 overexpression and TGFβ1 Cancer Research. 80: 5099-5099. DOI: 10.1158/1538-7445.Am2020-5099 |
0.418 |
|
| 2020 |
Raeeszadeh-Sarmazdeh M, Coban M, Sankaran B, Radisky E. Engineering protein therapeutics for cancer based on the natural matrix metalloproteinase inhibitor TIMP‐1 The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.04889 |
0.425 |
|
| 2019 |
Raeeszadeh-Sarmazdeh M, Greene KA, Sankaran B, Downey GP, Radisky DC, Radisky ES. Directed evolution of the metalloproteinase inhibitor TIMP-1 reveals that its N- and C-terminal domains cooperate in matrix metalloproteinase recognition. The Journal of Biological Chemistry. PMID 31040180 DOI: 10.1074/Jbc.Ra119.008321 |
0.465 |
|
| 2019 |
Mehner C, Radisky ES. Bad Tumors Made Worse: SPINK1. Frontiers in Cell and Developmental Biology. 7: 10. PMID 30778387 DOI: 10.3389/Fcell.2019.00010 |
0.325 |
|
| 2019 |
Ma H, Hockla A, Mehner C, Coban M, Papo N, Radisky DC, Radisky ES. PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma. Scientific Reports. 9: 1844. PMID 30755669 DOI: 10.1038/S41598-018-38362-0 |
0.32 |
|
| 2019 |
Cohen I, Coban M, Shahar A, Sankaran B, Hockla A, Lacham S, Caulfield TR, Radisky ES, Papo N. Disulfide engineering of human Kunitz-type serine protease inhibitors enhances proteolytic stability and target affinity toward mesotrypsin. The Journal of Biological Chemistry. PMID 30700553 DOI: 10.1074/Jbc.Ra118.007292 |
0.405 |
|
| 2019 |
Mehner C, Miller E, Coban MA, Hockla A, Radisky DC, Radisky ES. Abstract 3758: Targeting ovarian cancer induced peritoneal carcinomatosis by inhibition of signaling axis between Interleukin-6 (IL-6) and serine protease inhibitor Kazal type 1 (SPINK1) Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3758 |
0.341 |
|
| 2019 |
Gabasa M, Ikemori R, Radisky E, Reguart N, Radisky D, Alcaraz J. Abstract 2021: Role of MMP1-PAR-1 crosstalk in the pro-tumorigenic senescent fibroblasts in large cell carcinoma of the lung Cancer Research. 79: 2021-2021. DOI: 10.1158/1538-7445.Am2019-2021 |
0.42 |
|
| 2018 |
Naftaly S, Cohen I, Shahar A, Hockla A, Radisky ES, Papo N. Mapping protein selectivity landscapes using multi-target selective screening and next-generation sequencing of combinatorial libraries. Nature Communications. 9: 3935. PMID 30258049 DOI: 10.1038/S41467-018-06403-X |
0.35 |
|
| 2018 |
Arkadash V, Radisky ES, Papo N. Combinatorial engineering of N-TIMP2 variants that selectively inhibit MMP9 and MMP14 function in the cell. Oncotarget. 9: 32036-32053. PMID 30174795 DOI: 10.18632/Oncotarget.25885 |
0.487 |
|
| 2018 |
Sananes A, Cohen I, Shahar A, Hockla A, De Vita E, Miller AK, Radisky ES, Papo N. A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering. The Journal of Biological Chemistry. PMID 29934309 DOI: 10.1074/Jbc.Ra117.000871 |
0.448 |
|
| 2018 |
Cohen I, Naftaly S, Ben-Zeev E, Hockla A, Radisky ES, Papo N. Pre-Equilibrium Competitive Library Screening for Tuning Inhibitor Association Rate and Specificity towards Serine Proteases. The Biochemical Journal. PMID 29535275 DOI: 10.1042/Bcj20180070 |
0.443 |
|
| 2018 |
Shirian J, Arkadash V, Cohen I, Sapir T, Radisky ES, Papo N, Shifman JM. Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of MMP-9 and MMP-14. Febs Letters. PMID 29473954 DOI: 10.1002/1873-3468.13016 |
0.461 |
|
| 2018 |
Alcaraz J, Gabasa M, Ikemori R, Reguart N, Radisky E, Radisky D. Abstract 994: Cancer cells induce a protumorigenic senescent phenotype in fibroblasts through MMP1 but not autophagy in large cell carcinoma of the lung Cancer Research. 78: 994-994. DOI: 10.1158/1538-7445.Am2018-994 |
0.4 |
|
| 2018 |
Mehner C, Coban MA, Hockla A, Radisky DC, Radisky ES. Abstract 442: Serine protease inhibitor Kazal type 1 (SPINK1) drives anoikis resistance in ovarian clear cell carcinoma Cancer Research. 78: 442-442. DOI: 10.1158/1538-7445.Am2018-442 |
0.41 |
|
| 2017 |
Radisky ES, Sarmazdeh MR, Radisky DC. Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer. Journal of Cellular Biochemistry. PMID 28585723 DOI: 10.1002/Jcb.26185 |
0.488 |
|
| 2017 |
Kayode O, Huang Z, Soares AS, Caulfield TR, Dong Z, Bode AM, Radisky ES. Small molecule inhibitors of mesotrypsin from a structure-based docking screen. Plos One. 12: e0176694. PMID 28463992 DOI: 10.1371/Journal.Pone.0176694 |
0.382 |
|
| 2017 |
Arkadash V, Yosef G, Shirian J, Cohen I, Horev Y, Grossman M, Sagi I, Radisky ES, Shifman JM, Papo N. Development of high-affinity and high-specificity inhibitors of metalloproteinase 14 through computational design and directed evolution. The Journal of Biological Chemistry. PMID 28087697 DOI: 10.1074/Jbc.M116.756718 |
0.482 |
|
| 2016 |
Kayode O, Wang R, Pendlebury DF, Cohen I, Henin RD, Hockla A, Soares AS, Papo N, Caulfield TR, Radisky ES. An Acrobatic Substrate Metamorphosis Reveals a Requirement for Substrate Conformational Dynamics in Trypsin Proteolysis. The Journal of Biological Chemistry. PMID 27810896 DOI: 10.1074/Jbc.M116.758417 |
0.314 |
|
| 2016 |
Cichon MA, Moruzzi ME, Shqau TA, Miller E, Mehner C, Ethier SP, Copland JA, Radisky ES, Radisky DC. MYC is a crucial mediator of TGFβ-induced invasion in basal breast cancer. Cancer Research. PMID 27197167 DOI: 10.1158/0008-5472.Can-15-3465 |
0.332 |
|
| 2016 |
Cohen I, Kayode O, Hockla A, Sankaran B, Radisky DC, Radisky ES, Papo N. Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy. The Biochemical Journal. PMID 26957636 DOI: 10.1042/Bj20151410 |
0.465 |
|
| 2015 |
Mehner C, Miller E, Nassar A, Bamlet WR, Radisky ES, Radisky DC. Tumor cell expression of MMP3 as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinoma. Genes & Cancer. 6: 480-9. PMID 26807201 DOI: 10.18632/Genesandcancer.90 |
0.429 |
|
| 2015 |
Mehner C, Oberg AL, Kalli KR, Nassar A, Hockla A, Pendlebury D, Cichon MA, Goergen KM, Maurer MJ, Goode EL, Keeney GL, Jatoi A, Sahin-Tóth M, Copland JA, Radisky DC, ... Radisky ES, et al. Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. Oncotarget. 6: 35737-35754. PMID 26437224 DOI: 10.18632/Oncotarget.5927 |
0.385 |
|
| 2015 |
Alloy AP, Kayode O, Wang R, Hockla A, Soares AS, Radisky ES. Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as Substrates. The Journal of Biological Chemistry. PMID 26175157 DOI: 10.1074/Jbc.M115.662429 |
0.445 |
|
| 2015 |
Radisky ES, Radisky DC. Matrix metalloproteinases as breast cancer drivers and therapeutic targets. Frontiers in Bioscience (Landmark Edition). 20: 1144-63. PMID 25961550 DOI: 10.2741/4364 |
0.445 |
|
| 2014 |
Pendlebury D, Wang R, Henin RD, Hockla A, Soares AS, Madden BJ, Kazanov MD, Radisky ES. Sequence and conformational specificity in substrate recognition: several human Kunitz protease inhibitor domains are specific substrates of mesotrypsin. The Journal of Biological Chemistry. 289: 32783-97. PMID 25301953 DOI: 10.1074/Jbc.M114.609560 |
0.438 |
|
| 2014 |
Szabó A, Salameh MA, Ludwig M, Radisky ES, Sahin-Tóth M. Tyrosine sulfation of human trypsin steers S2' subsite selectivity towards basic amino acids. Plos One. 9: e102063. PMID 25010489 DOI: 10.1371/Journal.Pone.0102063 |
0.359 |
|
| 2014 |
Mehner C, Miller E, Khauv D, Nassar A, Oberg AL, Bamlet WR, Zhang L, Waldmann J, Radisky ES, Crawford HC, Radisky DC. Tumor cell-derived MMP3 orchestrates Rac1b and tissue alterations that promote pancreatic adenocarcinoma. Molecular Cancer Research : McR. 12: 1430-9. PMID 24850902 DOI: 10.1158/1541-7786.Mcr-13-0557-T |
0.418 |
|
| 2014 |
Mehner C, Hockla A, Miller E, Ran S, Radisky DC, Radisky ES. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget. 5: 2736-49. PMID 24811362 DOI: 10.18632/Oncotarget.1932 |
0.431 |
|
| 2013 |
Batra J, Soares AS, Mehner C, Radisky ES. Matrix metalloproteinase-10/TIMP-2 structure and analyses define conserved core interactions and diverse exosite interactions in MMP/TIMP complexes. Plos One. 8: e75836. PMID 24073280 DOI: 10.1371/Journal.Pone.0075836 |
0.456 |
|
| 2013 |
Chen F, Radisky ES, Das P, Batra J, Hata T, Hori T, Baine AM, Gardner L, Yue MY, Bu G, del Zoppo G, Patel TC, Nguyen JH. TIMP-1 attenuates blood-brain barrier permeability in mice with acute liver failure. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 33: 1041-9. PMID 23532086 DOI: 10.1038/Jcbfm.2013.45 |
0.345 |
|
| 2013 |
Radisky ES. PRSS3/mesotrypsin in prostate cancer progression: implications for translational medicine. Asian Journal of Andrology. 15: 439-40. PMID 23503422 DOI: 10.1038/Aja.2013.14 |
0.356 |
|
| 2013 |
Batra J, Szabó A, Caulfield TR, Soares AS, Sahin-Tóth M, Radisky ES. Long-range electrostatic complementarity governs substrate recognition by human chymotrypsin C, a key regulator of digestive enzyme activation. The Journal of Biological Chemistry. 288: 9848-59. PMID 23430245 DOI: 10.1074/Jbc.M113.457382 |
0.38 |
|
| 2013 |
Mehner C, Batra J, Robinson J, Radisky DC, Radisky ES. Abstract 5069: Engineering TIMP-1 for selective MMP inhibition and future use as a protein therapeutic. Cancer Research. 73: 5069-5069. DOI: 10.1158/1538-7445.Am2013-5069 |
0.488 |
|
| 2012 |
Hockla A, Miller E, Salameh MA, Copland JA, Radisky DC, Radisky ES. PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer. Molecular Cancer Research : McR. 10: 1555-66. PMID 23258495 DOI: 10.1158/1541-7786.Mcr-12-0314 |
0.323 |
|
| 2012 |
Batra J, Robinson J, Mehner C, Hockla A, Miller E, Radisky DC, Radisky ES. PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1). Plos One. 7: e50028. PMID 23185522 DOI: 10.1371/Journal.Pone.0050028 |
0.478 |
|
| 2012 |
Stallings-Mann ML, Waldmann J, Zhang Y, Miller E, Gauthier ML, Visscher DW, Downey GP, Radisky ES, Fields AP, Radisky DC. Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression. Science Translational Medicine. 4: 142ra95. PMID 22786680 DOI: 10.1126/Scitranslmed.3004062 |
0.361 |
|
| 2012 |
Salameh MA, Soares AS, Alloy A, Radisky ES. Presence versus absence of hydrogen bond donor Tyr-39 influences interactions of cationic trypsin and mesotrypsin with protein protease inhibitors. Protein Science : a Publication of the Protein Society. 21: 1103-12. PMID 22610453 DOI: 10.1002/Pro.2097 |
0.436 |
|
| 2012 |
Liu H, Radisky DC, Yang D, Xu R, Radisky ES, Bissell MJ, Bishop JM. MYC suppresses cancer metastasis by direct transcriptional silencing of αv and β3 integrin subunits. Nature Cell Biology. 14: 567-74. PMID 22581054 DOI: 10.1038/Ncb2491 |
0.34 |
|
| 2012 |
Justilien V, Regala RP, Tseng IC, Walsh MP, Batra J, Radisky ES, Murray NR, Fields AP. Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential. Plos One. 7: e35040. PMID 22545096 DOI: 10.1371/Journal.Pone.0035040 |
0.438 |
|
| 2012 |
Batra J, Robinson J, Soares AS, Fields AP, Radisky DC, Radisky ES. Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure. The Journal of Biological Chemistry. 287: 15935-46. PMID 22427646 DOI: 10.1074/Jbc.M112.341156 |
0.454 |
|
| 2012 |
Justilien V, Regala RP, Tseng I, Walsh MP, Batra J, Radisky ES, Murray NR, Fields AP. Abstract LB-204: Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-204 |
0.413 |
|
| 2011 |
Salameh MA, Soares AS, Hockla A, Radisky DC, Radisky ES. The P(2)' residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activity. The Biochemical Journal. 440: 95-105. PMID 21806544 DOI: 10.1042/Bj20110788 |
0.477 |
|
| 2011 |
Szabó A, Héja D, Szakács D, Zboray K, Kékesi KA, Radisky ES, Sahin-Tóth M, Pál G. High affinity small protein inhibitors of human chymotrypsin C (CTRC) selected by phage display reveal unusual preference for P4' acidic residues. The Journal of Biological Chemistry. 286: 22535-45. PMID 21515688 DOI: 10.1074/Jbc.M111.235754 |
0.386 |
|
| 2011 |
Mehner C, Miller E, Radisky DC, Radisky ES. Abstract 1497: Matrix metalloproteinase-9 mediates growth, invasion, and metastasis of human breast cancer cells Cancer Research. 71: 1497-1497. DOI: 10.1158/1538-7445.Am2011-1497 |
0.373 |
|
| 2010 |
Salameh MA, Soares AS, Navaneetham D, Sinha D, Walsh PN, Radisky ES. Determinants of affinity and proteolytic stability in interactions of Kunitz family protease inhibitors with mesotrypsin. The Journal of Biological Chemistry. 285: 36884-96. PMID 20861008 DOI: 10.1074/Jbc.M110.171348 |
0.43 |
|
| 2010 |
Radisky ES. Cathepsin D: Regulation in mammary gland remodeling, misregulation in breast cancer. Cancer Biology & Therapy. 10: 467-70. PMID 20647745 DOI: 10.4161/Cbt.10.5.12855 |
0.375 |
|
| 2010 |
Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. Journal of Mammary Gland Biology and Neoplasia. 15: 201-12. PMID 20440544 DOI: 10.1007/S10911-010-9177-X |
0.444 |
|
| 2010 |
Orlichenko L, Geyer R, Yanagisawa M, Khauv D, Radisky ES, Anastasiadis PZ, Radisky DC. The 19-amino acid insertion in the tumor-associated splice isoform Rac1b confers specific binding to p120 catenin. The Journal of Biological Chemistry. 285: 19153-61. PMID 20395297 DOI: 10.1074/Jbc.M109.099382 |
0.336 |
|
| 2010 |
Hockla A, Radisky DC, Radisky ES. Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109. Breast Cancer Research and Treatment. 124: 27-38. PMID 20035377 DOI: 10.1007/S10549-009-0699-0 |
0.405 |
|
| 2010 |
Salameh MA, Robinson JL, Navaneetham D, Sinha D, Madden BJ, Walsh PN, Radisky ES. The amyloid precursor protein/protease nexin 2 Kunitz inhibitor domain is a highly specific substrate of mesotrypsin. The Journal of Biological Chemistry. 285: 1939-49. PMID 19920152 DOI: 10.1074/Jbc.M109.057216 |
0.422 |
|
| 2008 |
Salameh MA, Soares AS, Hockla A, Radisky ES. Structural basis for accelerated cleavage of bovine pancreatic trypsin inhibitor (BPTI) by human mesotrypsin. The Journal of Biological Chemistry. 283: 4115-23. PMID 18077447 DOI: 10.1074/Jbc.M708268200 |
0.428 |
|
| 2007 |
Radisky ES, Radisky DC. Stromal induction of breast cancer: inflammation and invasion. Reviews in Endocrine & Metabolic Disorders. 8: 279-87. PMID 17447144 DOI: 10.1007/S11154-007-9037-1 |
0.351 |
|
| 2006 |
Radisky ES, Lee JM, Lu CJ, Koshland DE. Insights into the serine protease mechanism from atomic resolution structures of trypsin reaction intermediates. Proceedings of the National Academy of Sciences of the United States of America. 103: 6835-40. PMID 16636277 DOI: 10.1073/Pnas.0601910103 |
0.462 |
|
| 2005 |
Radisky ES, Lu CJ, Kwan G, Koshland DE. Role of the intramolecular hydrogen bond network in the inhibitory power of chymotrypsin inhibitor 2. Biochemistry. 44: 6823-30. PMID 15865427 DOI: 10.1021/Bi047301W |
0.508 |
|
| 2004 |
Radisky ES, Kwan G, Karen Lu CJ, Koshland DE. Binding, proteolytic, and crystallographic analyses of mutations at the protease-inhibitor interface of the subtilisin BPN'/chymotrypsin inhibitor 2 complex. Biochemistry. 43: 13648-56. PMID 15504027 DOI: 10.1021/Bi048797K |
0.537 |
|
| 2003 |
Radisky ES, King DS, Kwan G, Koshland DE. The role of the protein core in the inhibitory power of the classic serine protease inhibitor, chymotrypsin inhibitor 2. Biochemistry. 42: 6484-92. PMID 12767231 DOI: 10.1021/Bi034275D |
0.515 |
|
| 2002 |
Radisky ES, Koshland DE. A clogged gutter mechanism for protease inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 99: 10316-21. PMID 12142461 DOI: 10.1073/Pnas.112332899 |
0.513 |
|
| 2000 |
Radisky ES, Poulter CD. Squalene synthase: steady-state, pre-steady-state, and isotope-trapping studies. Biochemistry. 39: 1748-60. PMID 10677224 DOI: 10.1021/Bi9915014 |
0.504 |
|
| 1999 |
Wu Z, Demma M, Strickland CL, Radisky ES, Poulter CD, Le HV, Windsor WT. Farnesyl protein transferase: identification of K164 alpha and Y300 beta as catalytic residues by mutagenesis and kinetic studies. Biochemistry. 38: 11239-49. PMID 10471273 DOI: 10.1021/Bi990583T |
0.465 |
|
| Show low-probability matches. |
